Document:

LOAN December 23, 2020

   
 LOAN
 AGREEMENT
 December 23, 2020
  
 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$7,500 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on December 23, 2020.

  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from December 23, 2020 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Richard N. Jeffs
	 Cell MedX (Canada) Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ Richard N. Jeffs
	 /s/  Yanika Silina

	 Richard N. Jeffs
	 Yanika Silina, Director

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
 
  
 PROMISSORY NOTE
  
 	 Principal Amount: CDN$7,500
	 December 23, 2020

  
  
 FOR VALUE RECEIVED Cell MedX (Canada) Corp., (the “Borrower”) promises to pay on demand to the order of Richard N. Jeffs (the “Lender”) the sum of $7,500 lawful money of Canada (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from December 23, 2020 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
  
  
 BORROWER
 Cell MedX (Canada) Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, DirectorLOAN January 21, 2021

   
 LOAN
 AGREEMENT
 January 21, 2021
  
 Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$45,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on January 21, 2021.
  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from January 21, 2021 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Rain Communications Corp.
	 Cell MedX Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ Ralph Biggar
	 /s/  Yanika Silina

	 Ralph Biggar, President
	 Yanika Silina, CFO

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
 PROMISSORY NOTE
  
 	 Principal Amount: USD$45,000
	 January 21, 2021

  
  
 FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Rain Communications Corp. (the “Lender”) the sum of $45,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from January 21, 2021 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
  
  
 BORROWER
 Cell MedX Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, CFOLOAN February 16, 2021

   
 LOAN
 AGREEMENT
 February 16, 2021
  
 Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$30,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on February 16, 2021.
  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from February 16, 2021 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Rain Communications Corp.
	 Cell MedX Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ Ralph Biggar
	 /s/  Yanika Silina

	 Ralph Biggar, President
	 Yanika Silina, CFO

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
 PROMISSORY NOTE
  
 	 Principal Amount: USD$30,000
	 February 16, 2021

  
  
 FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Rain Communications Corp. (the “Lender”) the sum of $30,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from February 16, 2021 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
  
  
 BORROWER
 Cell MedX Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, CFOExhibit 4.1

 

	NUMBER	 	_______ UNITS
	 	 	 
	U-__________	 	 

 

	SEE REVERSE FOR CERTAIN DEFINITIONS	CHARDAN NEXTECH ACQUISITION 2 CORP.	 
	 	 	 
	 	 	CUSIP 159561208

 

UNITS CONSISTING OF ONE SHARE OF COMMON STOCK
AND

ONE-THIRD OF ONE WARRANT, EACH WHOLE WARRANT
ENTITLING THE HOLDER TO

PURCHASE ONE SHARE OF COMMON STOCK

 

	THIS CERTIFIES THAT 	 	 

 

	is the owner of	 	Units.

 

Each Unit (“Unit”) consists of one
share of common stock, par value $.0001 per share, of Chardan NexTech Acquisition 2 Corp., a Delaware corporation (the “Company”),
and one-third of one warrant. Each whole warrant entitles the holder to purchase one share of common stock of the Company at $11.50 per
share (subject to adjustment), upon the later to occur of (i) the Company’s completion of a merger, share exchange, asset acquisition,
stock purchase, recapitalization, reorganization or other similar business combination, with one or more target businesses (a “Business
Combination”) or (ii) 12 months from the closing of the Company’s initial public offering (the “IPO”). Each warrant
expires 5 years after the completion of our initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption
or liquidation.

 

The common stock and warrant(s) comprising the
Unit(s) represented by this certificate are not transferable separately until the 90th day after the date of the prospectus relating to
the IPO, unless Chardan Capital Markets, LLC informs the Company of its decision to allow earlier separate trading, provided that the
Company has filed with the Securities and Exchanges Commission a Current Report on Form 8-K, which includes an audited balance sheet reflecting
the Company’s receipt of the gross proceeds of the IPO.

 

The terms of the warrants are governed by a warrant
agreement (the “Warrant Agreement”), dated as of [·], 2021, between the Company
and Continental Stock Transfer & Trust Company, as the warrant agent, and are subject to the terms and provisions contained therein,
all of which terms and provisions the holder of this certificate consents to by acceptance hereof. Copies of the Warrant Agreement are
on file at the office of the warrant agent at 1 State Street, 20th Floor, New York, New York 10004, and are available to any warrant holder
on written request and without cost.

 

This certificate is not valid unless countersigned
by the Transfer Agent and Registrar of the Company.

 

Witness the facsimile seal of the Company and
the facsimile signatures of its duly authorized officers.

 

[Corporate Seal]

 

This Unit Certificate shall be governed and construed
in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles thereof.

 

By:

	 	 	 
	Chairman	 	Secretary

 

Chardan NexTech Acquisition 2 Corp.

 

The Company will furnish without
charge to each stockholder who so requests, a statement of the powers, designations, preferences and relative, participating, optional
or other special rights of each class of shares or series thereof of the Company and the qualifications, limitations, or restrictions
of such preferences and/or rights.

 

The following abbreviations,
when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to
applicable laws or regulations:

 

	TEN COM –	as tenants in common UNIF GIFT MIN ACT - _____ Custodian ______
	TEN ENT –	as tenants by the entireties (Cust) (Minor)
	JT TEN –	as joint tenants with right of survivorship under Uniform Gifts to Minors

 

	 	and not as tenants in common Act ______________
	 	(State)

 

Additional abbreviations may also be used though
not in the above list.

 

For value received, ___________________________
hereby sells, assigns and transfers unto

 

     

     

    

 

PLEASE INSERT SOCIAL SECURITY OR OTHER

 

IDENTIFYING NUMBER OF ASSIGNEE

	 	 

 

	 
	(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)
	 
	 
	 
	 

 

	 	Units

represented by the within Certificate, and do hereby irrevocably
constitute and appoint

	 	Attorney

 

to transfer the said Units on the books of
the within named Company with full power of substitution in the premises.

 

	Dated	 	 

 

	 	 	 
	 	Notice:	The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.
	 	 	 

Signature(s) Guaranteed:

	 	 
	THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION
	(BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH
	MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM,
	PURSUANT TO SEC RULE 17Ad-15).	 

 

The holder of this certificate shall be entitled
to receive funds with respect to the underlying share of common stock from the trust account established in connection with the Company’s
initial public offering only in the event of the Company’s liquidation upon failure to consummate a business combination within
the required time period set forth in the Company’s Amended and Restated Certificate of Incorporation (the “Certificate”),
as the same may be amended from time to time, or if the holder seeks to convert his or her respective shares of common stock underlying
the Unit upon consummation of such business combination or in connection with certain amendments to the Certificate. In no other circumstances
shall the holder have any right or interest of any kind in or to the trust account.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]